BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지

Phosphotyrosine Protein Phosphatase Activity Is Inversely Related to Metastatic Ability in Rat Prostatic Tumor Cell Subclonal Lines

  • Lee, Han-Soo (Division of Life Sciences, College of Natural Sciences, Kangwon National University)
  • Received : 1996.04.25
  • Published : 1996.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

In clonal sublines with different metastatic ability derived from Dunning rat prostate tumor, phosphoamino acid levels of cellular proteins were determined. Cell lines with high metastatic ability exhibited 5-fold higher phosphotyrosine level than did cell lines with low metastatic ability, while the contents of phosphoserine and phosphothreonine were similar among cell lines examined, All cell lines showed similar activities of protein tyrosine kinases as well as overall protein kinases. Phosphotyrosine protein phosphatase (PTPP) activities of the cells with high metastatic ability were very low, compared to those of the cells with low metastatic ability, suggesting that the different phosphotyrosine levels among the cell lines were due to the difference in PTPP activities rather than protein tyrosine kinase activities. Cellular activities of prostatic acid phosphatase (PAcP), which has been reported to possess phosphotyrosine protein phosphatase activity, were shown to be inversely related to the phosphotyrosine levels and metastatic abilities of the prostate tumor cells, These results suggest that cellular PAcP activity, regulating phosphotyrosine levels of cellular proteins, is closely connected with the metastatic process in prostate tumor cells and can be utilized as a good biochemical marker for the diagnosis of metastasis of prostate tumor.

Keywords

References

  1. J. Virol. v.42 Beemon, K.;Ryden, T.;McNelly, E.A.
  2. J. Biol. Chem. v.258 Chernoff, J.;Li, H.C.;Cheng, Y.S.E.;Chen, L.B.
  3. J. Virol. v.46 Cooper, J.;Nakamura, K.D.;Hunter, T.;Weber, M.J.
  4. Cancer Res. v.38 Fidler, I.J.
  5. Advances in Cancer Research, Vol. 28 Fidler, I.J.;Gersten, D.M.;Hart, I.R.;Klein, G.(ed.);Weinhouse, S.(ed.)
  6. Annu. Rev. Biochem. v.54 Hunter, T.;Cooper, J.A. https://doi.org/10.1146/annurev.bi.54.070185.004341
  7. Cancer Res. v.42 Isaacs, J.T.;Wake, N.;Coffey, D.S.;Sandberg, A.
  8. Nature v.227 Laemmli, U.K. https://doi.org/10.1038/227680a0
  9. Biochem. J. v.277 Lee, H.;Chu, T.M.;Li, S.S.L.;Lee, C.L. https://doi.org/10.1042/bj2770759
  10. J. Biol. Chem. v.268 Lee, H.;Chose-Dastidar, J.;Winawer, S.;Friedman, E.
  11. J. Biol. Chem. v.268 Lee, H.;Hsu, S.;Winawer, S.;Friedman, E.
  12. Korean Biochem. J. (presently J. Biochem. Mol. Biol.) v.27 Lee, H.
  13. Eur. J. Biochem. v.138 Li, H.C.;Chemoff, J.;Chen, L.B.;Kirschonbaum, A. https://doi.org/10.1111/j.1432-1033.1984.tb07879.x
  14. Biochemistry v.22 Lin, M.F.;Lee, C.L.;Li, S.S.L.;Chu, T.M. https://doi.org/10.1021/bi00274a009
  15. J. Biol. Chem. v.260 Lin, M.F.;Lee, P.;Clinton, G.M.
  16. Mol. Cell. Biol. v.6 Lin, M.F.;Lee, C.L.;Clinton, G.M. https://doi.org/10.1128/MCB.6.12.4753
  17. Biochem. J. v.235 Lin, M.F.;Clinton, G.M. https://doi.org/10.1042/bj2350351
  18. Mol. Cell. Biol. v.8 Lin, M.F.;Clinton, G.M. https://doi.org/10.1128/MCB.8.12.5477
  19. Cancer Lett. v.14 Loor, R.M.;Wang, M.C.;Valenzuela, L.;Chu, T.M. https://doi.org/10.1016/0304-3835(81)90010-0
  20. Cancer Res. v.44 Lowe, F.C.;Isaacs, J.T.
  21. Cancer Res. Ther. v.5 Nicolson, G.L.
  22. Methods Enzymol. v.99 Roskoski, R. Jr.
  23. Cancer Treat. Rev. v.2 Salsbury, A.J. https://doi.org/10.1016/S0305-7372(75)80015-6
  24. Cell v.20 Sefton, B.M.;Hunter, T.;Beemon, K.;Eckhart, W. https://doi.org/10.1016/0092-8674(80)90327-X
  25. The Enzymes, Vol. 17 White, M.F.;Kahn, C.R.;Boyer, P.D.(ed.);Krebs, E.G.(ed.)
  26. Am. J. Med. v.56 Yam. L.T. https://doi.org/10.1016/0002-9343(74)90630-5
  27. Cancer Res. v.17 Zeidman, I.